Cargando…
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
Multiple myeloma (MM) is a clinically and genetically heterogeneous plasma cell (PC) malignancy. Whole-exome sequencing has identified therapeutically targetable mutations such as those in the mitogen-activated protein kinase (MAPK) pathway, which are the most prevalent MM mutations. We used deep se...
Autores principales: | Lionetti, Marta, Barbieri, Marzia, Todoerti, Katia, Agnelli, Luca, Marzorati, Simona, Fabris, Sonia, Ciceri, Gabriella, Galletti, Serena, Milesi, Giulia, Manzoni, Martina, Mazzoni, Mara, Greco, Angela, Tonon, Giovanni, Musto, Pellegrino, Baldini, Luca, Neri, Antonino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695180/ https://www.ncbi.nlm.nih.gov/pubmed/26090869 |
Ejemplares similares
-
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
por: Lionetti, Marta, et al.
Publicado: (2015) -
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature
por: Lionetti, Marta, et al.
Publicado: (2016) -
KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019) -
Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023) -
KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)